Citron Reiterates $1 Target On Accelerate Diagnostics

January 20, 2016 1:23 PM | 1 min read | Make a Comment

Shares of

Accelerate Diagnostics IncAXDX

plunged to a new 52-week low of $13.78 on Wednesday after Citron Research reiterated a $1 price target on the stock. Accelerate Diagnostics is an in-vitro diagnostics company providing solutions to improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Citron Research

argued back in March, 2015 that Accelerate Diagnostics is a "controversial stock" with no "viable" commercial product on the horizon after 11 years of "unfulfilled promises." The research report placed a $1.00 per share price target within 18 months. Citron Research took to Twitter on Wednesday and compared Accelerate Diagnostics to Theranos, a blood-testing startup company that has been investigated by U.S. health regulators.

Market News and Data brought to you by Benzinga APIs

Posted In: News Short Sellers Short Ideas Movers Trading Ideas Accelerate Diagnostics Citron Research Theranos

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!